Percentage of tumor in prostatectomy specimens a study of american veterans

American Journal of Clinical Pathology

Volumn 131, Issue 1, 2009, Pages 86-91

  Vollmer, Robin T ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Age; Grade; Percentage of tumor; Prostate cancer; Prostate specific antigen; Prostatectomy; Serum PSA; Survival; Tumor size

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; UNITED STATES; VETERANS;

EID: 58549094727     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPX5MAMNMFE6FQ     Document Type: Article

References (41)

1. Gleason DF. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic Pathology: The Prostate. Philadelphia, PA: Lea & Febiger; 1977:171-198.
2. Cantrell BB, DeKleerk DP, Eggleston JC, et al. Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. J Urol. 1981;125:516-520.
3. Kikuchi E, Scardino PT, Wheeler TM, et al. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol. 2004;172:508-511.
4. Jones TD, Koch MO, Lin H, et al. Visual estimate of tumour extent is not an independent predictor of prostate specific antigen recurrence. BJU Int. 2005;96:1253-1257.
5. Varkarakis M, Castro JE, Azzopardi JG. Prognosis of stage 1 carcinoma of the prostate. Proc R Soc Med. 1970;63:91-93.
6. Humphrey PA, Vollmer RT. Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens. Hum Pathol. 1990;21:799-804.
7. Foucar E, Haake G, Dalton L, et al. The area of cancer in transurethral resection specimens as a prognostic indicator in carcinoma of the prostate: a computer-assisted morphometric study. Hum Pathol. 1990;21:586-592.
8. Epstein JI, Carmichael M, Partin AW, et al. Is tumor volume an independent predictor of progression following radical prostatectomy? a multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol. 1993;149:1478-1481.
9. Ohori M, Goad JR, Wheeler TM, et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994;152:1843-1849.
10. Ohori M, Wheeler TM, Kattan MW, et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 1995;154:1818-1824.
11. Carmichael MJ, Veltri RW, Partin AW, et al. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol. 1995;153:1015-1019.
12. Watson RB, Civantos F, Soloway MS. Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology. 1996;48:80-90.
13. Theodorescu D, Broder SR, Boyd JC, et al. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer. 1997;80:2109-2119.
14. Stamey TA, McNeal JE, Yemoto CM, et al. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999;281:1395-1400.
15. Carvahal GF, Humphrey PA, Thorson P, et al. Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer. 2000;89:1308-1314.
16. Vollmer RT, Humphrey PA. The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer. Am J Clin Pathol. 2001;116:864-870.
17. Salomon L, Levrel O, Anastasiadis AG, et al. Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol. 2003;43:39-44.
18. Manoharan M, Civantos F, Kim SS, et al. Visual estimate of percent of carcinoma predicts recurrence after radical prostatectomy. J Urol. 2003;170:1194-1198.
19. Ramos CG, Roehl KA, Antenor JAV, et al. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol. 2004;172:137-140.
20. Cheng L, Koch MO, Juliar BE, et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol. 2005;23:2911-2917.
21. Guzzo TJ, Vira MA, Neway W, et al. Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy. Urology. 2007;69:1147-1151.
22. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540-545.
23. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
24. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439.
25. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929-943.
26. Vollmer RT, Montana GS. The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer. Clin Cancer Res. 1999;5:4119-4125.
27. Cieki JP. Editorial comment. J Urol. 2008;179:2185.
28. Collette L. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. Eur Urol. 2008;53:6-9.
29. Hosmer DW, Lemeshow S. Applied Survival Analysis. Regression Modeling of Time to Event Data. New York, NY: Wiley; 1999.
30. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley; 1989.
31. DeHoff RT, Rhines FN. Quantitative Microscopy. New York, NY: McGraw-Hill; 1968.
32. Vollmer RT, Humphrey PA. Tumor volume in prostate cancer and serum prostate-specific antigen: analysis from a kinetic viewpoint. Am J Clin Pathol. 2003;119:80-89.
33. Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, II: radical prostatectomy treated patients. J Urol. 1989;141:1076-1083.
34. Blackwell KL, Bostwick DG, Myers RP, et al. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen density. J Urol. 1994;151:1565-1570.
35. Kabalin JN, McNeal JE, Johnstone IM, et al. Serum prostate-specific antigen and the biologic progression of prostate cancer. Urology. 1995;46:65-70.
36. Moul JW, Sesterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995;274:1277-1281.
37. Pettaway CA, Troncoso P, Ramirez EI, et al. Prostate-specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998;160:437-442.
38. Moul JW, Connelly RR, Mooneyhan RM, et al. Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol. 1999;162:394-397.
39. Zhang W, Sesterhenn IA, Connelly RR, et al. Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. J Urol. 2000;163:131-136.
40. Stamey TA, Caldwell M, McNeal JE, et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004;172:1297-1301.
41. Aihara M, Lebovitz RM, Wheeler TM, et al. Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J Urol. 1994;151:1558-1564.